MediumCardiologyHeart failure with reduced ejection fractionca-mccqe1ca-rcpsc-im
A 76-year-old woman with a history of heart failure with reduced ejection fraction (LVEF 30%) and NYHA class II symptoms is on maximally tolerated ACE inhibitor and beta-blocker therapy. Her potassium is 4.6 mmol/L and eGFR is 55 mL/min/1.73 m². According to Canadian heart failure guidance, which additional medication class should be routinely added to improve morbidity and mortality, assuming no contraindications?